Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA.
Drug Discov Today. 2010 May;15(9-10):354-64. doi: 10.1016/j.drudis.2010.03.009. Epub 2010 Mar 23.
The unique properties of cancer- and metastasis-initiating cells endowed with a high self-renewal and aberrant differentiation potential (including their elevated expression levels of anti-apoptotic factors, multidrug transporters, and DNA repair and detoxifying enzymes) might be associated with their resistance to current clinical cancer therapies and disease recurrence. The eradication of cancer- and metastasis-initiating cells by molecular targeting of distinct deregulated signaling elements that might contribute to their sustained growth, survival, and treatment resistance, therefore, is of immense therapeutic interest. These novel targeted approaches should improve the efficacy of current therapeutic treatments against highly aggressive, metastatic, recurrent, and lethal cancers.
具有高自我更新和异常分化潜能(包括其抗凋亡因子、多药转运体、DNA 修复和解毒酶的高表达水平)的癌症起始细胞和转移起始细胞的独特特性,可能与它们对当前临床癌症治疗和疾病复发的抵抗有关。通过针对可能有助于其持续生长、存活和治疗抵抗的特定失调信号转导元件的分子靶向来根除癌症起始细胞和转移起始细胞,因此具有巨大的治疗意义。这些新的靶向方法应该提高当前针对高度侵袭性、转移性、复发性和致命性癌症的治疗效果。